About Hememics Biotechnologies
Hememics Biotechnologies is a company based in Gaithersburg (United States) founded in 2009 by David Huy Ho and John L Warden.. Hememics Biotechnologies has raised $4.6 million across 5 funding rounds from investors including HHS, TEDCO and American Vietnamese Investment Partners. The company has 13 employees as of December 31, 2022. Hememics Biotechnologies offers products and services including HemBox, Hem Chip Reader, and Biochip. Hememics Biotechnologies operates in a competitive market with competitors including DermaSensor, Souzhou Ribo Life Science, Zerigo Health, Cardea Bio and Senzo, among others.
- Headquarter Gaithersburg, United States
- Employees 13 as on 31 Dec, 2022
- Founders David Huy Ho, John L Warden
-
Sectors
TechnologyHealthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hememics Biotechnologies, Inc.
-
Annual Revenue
$00as on May 25, 2018
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.6 M (USD)
in 5 rounds
-
Latest Funding Round
$2 M (USD), Seed
May 25, 2023
-
Investors
HHS
& 2 more
-
Employee Count
13
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hememics Biotechnologies
Hememics Biotechnologies offers a comprehensive portfolio of products and services, including HemBox, Hem Chip Reader, and Biochip. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Handheld device for rapid detection of substances in various fields
Reader for accurate biochip results in testing applications
Multiplexed chip for simultaneous detection of multiple targets
Unlock access to complete
Unlock access to complete
Funding Insights of Hememics Biotechnologies
Hememics Biotechnologies has successfully raised a total of $4.6M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Seed — $2.0M
-
First Round
First Round
(01 Jul 2012)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Seed - Hememics Biotechnologies | Valuation |
investors |
|
| Dec, 2020 | Amount | Seed - Hememics Biotechnologies | Valuation |
investors |
|
| Dec, 2019 | Amount | Seed - Hememics Biotechnologies | Valuation | American Vietnamese Investment Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hememics Biotechnologies
Hememics Biotechnologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, TEDCO and American Vietnamese Investment Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund and startup accelerator programs focused on seed and early stage companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hememics Biotechnologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hememics Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hememics Biotechnologies Comparisons
Competitors of Hememics Biotechnologies
Hememics Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermaSensor, Souzhou Ribo Life Science, Zerigo Health, Cardea Bio and Senzo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Handheld diagnostic device for skin cancer lesions is developed.
|
|
| domain | founded_year | HQ Location |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| domain | founded_year | HQ Location |
Developer of UVB light therapy devices for monitoring Psoriasis, Vitiligo, and Eczema
|
|
| domain | founded_year | HQ Location |
Digital graphene biosensors are developed using machine learning.
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic devices for infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Next-generation sequencing is provided for microbiology testing applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hememics Biotechnologies
Frequently Asked Questions about Hememics Biotechnologies
When was Hememics Biotechnologies founded?
Hememics Biotechnologies was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Where is Hememics Biotechnologies located?
Hememics Biotechnologies is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of Hememics Biotechnologies?
John L Warden is the current CEO of Hememics Biotechnologies. They have also founded this company.
Is Hememics Biotechnologies a funded company?
Hememics Biotechnologies is a funded company, having raised a total of $4.6M across 5 funding rounds to date. The company's 1st funding round was a Seed of $2.5M, raised on Jul 01, 2012.
How many employees does Hememics Biotechnologies have?
As of Dec 31, 2022, the latest employee count at Hememics Biotechnologies is 13.
What does Hememics Biotechnologies do?
Founded in 2009 and headquartered in Gaithersburg, United States, HeMemics Biotechnologies operates in the biotechnology sector focused on biopreservation. Patented HeMeDri technology is utilized to create preservation solutions such as HemSol, which enable storage of mammalian cells and perishable biologics in desiccated or non-desiccated forms at cold or ambient temperatures. Customized stabilization services are provided for proteins, cells, and tissues in dried or non-dried formats to facilitate storage and transport.
Who are the top competitors of Hememics Biotechnologies?
Hememics Biotechnologies's top competitors include Nix, DermaSensor and Souzhou Ribo Life Science.
What products or services does Hememics Biotechnologies offer?
Hememics Biotechnologies offers HemBox, Hem Chip Reader, and Biochip.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.